|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.28 USD | -0.40% |
|
-0.34% | +29.90% |
| 07-22 | Celldex Therapeutics, Inc. - Special Call | |
| 07-22 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 2,769 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 53.44% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 2,185 | 2,254 | 2,287 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 69.89% | 3.16% | 1.48% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -8.13x | -8.13x | -11.1x |
| PBR | - | - | - | 2.25x | 3.43x | 4.8x | 4.71x | 5.13x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -0.7x | -470.33x | 0.4x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,146x | 251x | 19.7x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 904x | 204x | 16.3x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -6.38x | -6.08x | -10.1x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -6.32x | -6.07x | -8.13x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -7.79x | -8.03x | -11.7x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -12.8% | -12.5% | -8.55% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.339 | -4.34 | -3.175 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 2.416 | 11.04 | 140.3 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -342.6 | -371 | -227 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -345.7 | -371.2 | -281.3 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -330.1 | -367.5 | -291.1 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -584.1 | -515.1 | -481.8 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 35.28 | 35.28 | 35.28 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,492 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 2/27/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.16x | 908.81x | -6.41x | -.--% | 2.78B | |
| 32.08x | 5.72x | 17.39x | 1.03% | 46.35B | |
| -23.56x | 353.6x | -21.6x | -.--% | 40.13B | |
| 49.04x | 4.97x | 31.86x | -.--% | 36.33B | |
| 25.23x | 2.79x | 12.07x | -.--% | 34.6B | |
| 26.59x | 7.81x | 19.59x | 0.43% | 26.77B | |
| 34.86x | 5.67x | 26.04x | -.--% | 16.91B | |
| 22.54x | 1.98x | 8.69x | 1.17% | 13.05B | |
| 24.07x | 1.92x | 11.6x | -.--% | 13.05B | |
| Average | 20.30x | 143.70x | 11.03x | 0.29% | 25.55B | |
| Weighted average by Cap. | 22.10x | 76.59x | 11.85x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
